SCHEMBL711990

SCHEMBL711990

CCCNCc1nc2ccc3c(c2[nH]1)C(=O)c1ccccc1C3=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
HTT P42858 3/20 0.39
POLB P06746 2/20 0.39
HPGD P15428 1/20 0.39
MAOA P21397 2/20 0.37
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CSNK2A3 Q8NEV1 1/20 0.36
MITF O75030 1/20 0.35
MAPK1 P28482 4/20 0.35
LMNA P02545 3/20 0.35
PKM P14618 1/20 0.35
TDP1 Q9NUW8 3/20 0.34
ALOX15 P16050 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10071932 0.83 TNKS2 (0.47) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL10044137 0.83 ALDH1A1 (0.39) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL712815 0.82 MAPT (0.40) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL12261351 0.81 PARP1 (0.51) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL12261358 0.80 PARP1 (0.46) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL711986 0.78 MAOA (0.43) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL711989 0.78 MAPT (0.40) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL719982 0.78 KMT2A (0.42) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL713071 0.78 PDE10A (0.37) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL713187 0.78 TRPV1 (0.39) MAPTALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US claimed
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US disclosed
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof TERT, ACIN1, AK2 MAPT 3490/4885SMN1; SMN2 3811/4885ALDH1A1 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.